Gain Therapeutics Files 2024 10-K
Ticker: GANX · Form: 10-K · Filed: Mar 27, 2025 · CIK: 1819411
| Field | Detail |
|---|---|
| Company | Gain Therapeutics, Inc. (GANX) |
| Form Type | 10-K |
| Filed Date | Mar 27, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, financials, pharmaceutical
TL;DR
Gain Therapeutics 2024 10-K is in: $27.1M assets, $16.2M liabilities.
AI Summary
Gain Therapeutics, Inc. filed its 2024 10-K on March 27, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company, incorporated in Delaware and headquartered in Bethesda, MD, operates in the pharmaceutical preparations sector. Key financial data points include total assets of $27.1 million and total liabilities of $16.2 million as of December 31, 2024.
Why It Matters
This filing provides investors with a comprehensive overview of Gain Therapeutics' financial health and operational performance for the past fiscal year, crucial for investment decisions.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Gain Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- $27.1M — Total Assets (As of December 31, 2024)
- $16.2M — Total Liabilities (As of December 31, 2024)
Key Players & Entities
- Gain Therapeutics, Inc. (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- 2025-03-27 (date) — Filing date
- 27132588 (dollar_amount) — Total assets as of December 31, 2024
- 16206680 (dollar_amount) — Total liabilities as of December 31, 2024
FAQ
What were Gain Therapeutics' total assets and liabilities as of December 31, 2024?
As of December 31, 2024, Gain Therapeutics reported total assets of $27,132,588 and total liabilities of $16,206,680.
When did Gain Therapeutics file its 2024 10-K report?
Gain Therapeutics filed its 2024 10-K report on March 27, 2025.
What is the primary business of Gain Therapeutics, Inc.?
Gain Therapeutics, Inc. is classified under Standard Industrial Classification code 2834, Pharmaceutical Preparations.
Where is Gain Therapeutics, Inc. headquartered?
Gain Therapeutics, Inc. is headquartered in Bethesda, MD, with its business and mail address listed at 4800 Hampden Lane, Suite 200.
What is the SEC file number for Gain Therapeutics?
The SEC file number for Gain Therapeutics is 001-40237.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 27, 2025 regarding Gain Therapeutics, Inc. (GANX).